Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | BMC Cardiovascular Disorders |
| Vol/bind | 10 |
| Sider (fra-til) | 6 |
| ISSN | 1471-2261 |
| DOI | |
| Status | Udgivet - 1 jan. 2010 |
Adgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study. / Sorensen, Rikke; Abildstrom, Steen Z; Weeke, Peter; Fosbol, Emil L; Folke, Fredrik; Hansen, Morten L; Hansen, Peter R; Madsen, Jan K; Abildgaard, Ulrik; Køber, Lars Valeur; Poulsen, Henrik E; Torp-Pedersen, Christian; Gislason, Gunnar H; Sørensen, Rikke; Abildstrom, Steen Z; Weeke, Peter; Fosbøl, Emil L; Folke, Fredrik; Hansen, Morten L; Hansen, Peter R; Madsen, Jan K; Abildgaard, Ulrik; Køber, Lars; Poulsen, Henrik E; Torp-Pedersen, Christian; Gislason, Gunnar H.
I: BMC Cardiovascular Disorders, Bind 10, 01.01.2010, s. 6.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study
AU - Sorensen, Rikke
AU - Abildstrom, Steen Z
AU - Weeke, Peter
AU - Fosbol, Emil L
AU - Folke, Fredrik
AU - Hansen, Morten L
AU - Hansen, Peter R
AU - Madsen, Jan K
AU - Abildgaard, Ulrik
AU - Køber, Lars Valeur
AU - Poulsen, Henrik E
AU - Torp-Pedersen, Christian
AU - Gislason, Gunnar H
AU - Sørensen, Rikke
AU - Abildstrom, Steen Z
AU - Weeke, Peter
AU - Fosbøl, Emil L
AU - Folke, Fredrik
AU - Hansen, Morten L
AU - Hansen, Peter R
AU - Madsen, Jan K
AU - Abildgaard, Ulrik
AU - Køber, Lars
AU - Poulsen, Henrik E
AU - Torp-Pedersen, Christian
AU - Gislason, Gunnar H
PY - 2010/1/1
Y1 - 2010/1/1
N2 - ABSTRACT: BACKGROUND: The optimal duration of clopidogrel treatment after percutaneous coronary intervention (PCI) is unclear. We studied the risk of death or recurrent myocardial infarction (MI) in relation to 6- and 12-months clopidogrel treatment among MI patients treated with PCI. METHODS: Using nationwide registers of hospitalizations and drug dispensing from pharmacies we identified 11 680 patients admitted with MI, treated with PCI and clopidogrel. Clopidogrel treatment was categorized in a 6-months and a 12-months regimen. Rates of death, recurrent MI or a combination of both were analyzed by the Kaplan Meier method and Cox proportional hazards models. Bleedings were compared between treatment regimens. RESULTS: The Kaplan Meier analysis indicated no benefit of the 12-months regimen compared with the 6-months in all endpoints. The Cox proportional hazards analysis confirmed these findings with hazard ratios for the 12-months regimen (the 6-months regimen used as reference) for the composite endpoint of 1.01 (confidence intervals 0.81-1.26) and 1.24 (confidence intervals 0.95-1.62) for Day 0-179 and Day 180-540 after discharge. Bleedings occurred in 3.5% and 4.1% of the patients in the 6-months and 12-months regimen (p=0.06). CONCLUSIONS: We found comparable rates of death and recurrent MI in patients treated with 6- and 12-months' clopidogrel. The potential benefit of prolonged clopidogrel treatment in a real-life setting remains uncertain.
AB - ABSTRACT: BACKGROUND: The optimal duration of clopidogrel treatment after percutaneous coronary intervention (PCI) is unclear. We studied the risk of death or recurrent myocardial infarction (MI) in relation to 6- and 12-months clopidogrel treatment among MI patients treated with PCI. METHODS: Using nationwide registers of hospitalizations and drug dispensing from pharmacies we identified 11 680 patients admitted with MI, treated with PCI and clopidogrel. Clopidogrel treatment was categorized in a 6-months and a 12-months regimen. Rates of death, recurrent MI or a combination of both were analyzed by the Kaplan Meier method and Cox proportional hazards models. Bleedings were compared between treatment regimens. RESULTS: The Kaplan Meier analysis indicated no benefit of the 12-months regimen compared with the 6-months in all endpoints. The Cox proportional hazards analysis confirmed these findings with hazard ratios for the 12-months regimen (the 6-months regimen used as reference) for the composite endpoint of 1.01 (confidence intervals 0.81-1.26) and 1.24 (confidence intervals 0.95-1.62) for Day 0-179 and Day 180-540 after discharge. Bleedings occurred in 3.5% and 4.1% of the patients in the 6-months and 12-months regimen (p=0.06). CONCLUSIONS: We found comparable rates of death and recurrent MI in patients treated with 6- and 12-months' clopidogrel. The potential benefit of prolonged clopidogrel treatment in a real-life setting remains uncertain.
U2 - 10.1186/1471-2261-10-6
DO - 10.1186/1471-2261-10-6
M3 - Journal article
C2 - 20113477
VL - 10
SP - 6
JO - B M C Cardiovascular Disorders
JF - B M C Cardiovascular Disorders
SN - 1471-2261
ER -